Dr. Cillian De Gascun:

The data from phase 3 clinical trials will be available at the end of November. A couple of companies have been quite bullish that they will be going to the Food and Drug Administration, FDA, at the end of November or the start of December to seek emergency use authorisation or early approval. It is very important for us to see what those data tell us about how the vaccine performs. Safety is paramount with any new vaccine. Efficacy is also important.